Conductance fluctuations in the presence of spin scattering

Electron transport through disordered systems that include spin scatterers is studied numerically. We consider three kinds of magnetic impurities: the Ising, the XY and the Heisenberg. By extending the transfer matrix method to include the spin degree of freedom, the two terminal conductance is calculated. The variance of conductance is halved as the number of spin components of the magnetic impurities increases. Application of the Zeeman field in the lead causes a further halving of the variance under certain conditions.Comment: to be published in Phys. Rev.

Intramolecular C–H and C–F Bond Oxygenation by Site-Differentiated Tetranuclear Manganese Models of the OEC

The dangler manganese center in the oxygen-evolving complex (OEC) of photosystem II plays an important role in the oxidation of water to dioxygen. Inspired by the structure of the OEC, we synthesized a series of site-differentiated tetra-manganese clusters [LMn_3(PhPz)_3OMn][OTf]_x (2: x= 2; 3: x = 1) that features an apical manganese ion—distinct from the others—that is appended to a trinuclear manganese core through an μ4-oxygen atom bridge. This cluster design was targeted to facilitate studies of high-valent Mn-oxo formation, which is a proposed step in the mechanism for water oxidation by the OEC. Terminal Mn-oxo species—supported by a multinuclear motif—were targeted by treating 2 and 3 with iodosobenzene. Akin to our previously reported iron complexes, intramolecular arene hydroxylation was observed to yield the C–H bond oxygenated complexes [LMn3(PhPz)_2(OArPz)OMn][OTf]x (5: x = 2; 6: x = 1). The fluorinated series [LMn_3(F_2ArPz)_3OMn][OTf]_x (8: x = 2; 9: x = 1) was also synthesized to mitigate the observed intramolecular hydroxylation. Treatment of 8 and 9 with iodosobenzene results in intramolecular arene C–F bond oxygenation as judged by electrospray ionization mass spectrometry. The observed aromatic C–H and C–F hydroxylation is suggestive of a putative high-valent terminal metal-oxo species, and it is one of the very few examples capable of oxygenating C–F bonds

Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer

FLAURA ClinicalTrials.gov number, NCT02296125BACKGROUND: Osimertinib is an oral, third-generation, irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that selectively inhibits both EGFR-TKI-sensitizing and EGFR T790M resistance mutations. We compared osimertinib with standard EGFR-TKIs in patients with previously untreated, EGFR mutation-positive advanced non-small-cell lung cancer (NSCLC). METHODS: In this double-blind, phase 3 trial, we randomly assigned 556 patients with previously untreated, EGFR mutation-positive (exon 19 deletion or L858R) advanced NSCLC in a 1:1 ratio to receive either osimertinib (at a dose of 80 mg once daily) or a standard EGFR-TKI (gefitinib at a dose of 250 mg once daily or erlotinib at a dose of 150 mg once daily). The primary end point was investigator-assessed progression-free survival. RESULTS: The median progression-free survival was significantly longer with osimertinib than with standard EGFR-TKIs (18.9 months vs. 10.2 months; hazard ratio for disease progression or death, 0.46; 95% confidence interval [CI], 0.37 to 0.57; P<0.001). The objective response rate was similar in the two groups: 80% with osimertinib and 76% with standard EGFR-TKIs (odds ratio, 1.27; 95% CI, 0.85 to 1.90; P=0.24). The median duration of response was 17.2 months (95% CI, 13.8 to 22.0) with osimertinib versus 8.5 months (95% CI, 7.3 to 9.8) with standard EGFR-TKIs. Data on overall survival were immature at the interim analysis (25% maturity). The survival rate at 18 months was 83% (95% CI, 78 to 87) with osimertinib and 71% (95% CI, 65 to 76) with standard EGFR-TKIs (hazard ratio for death, 0.63; 95% CI, 0.45 to 0.88; P=0.007 [nonsignificant in the interim analysis]). Adverse events of grade 3 or higher were less frequent with osimertinib than with standard EGFR-TKIs (34% vs. 45%). CONCLUSIONS: Osimertinib showed efficacy superior to that of standard EGFR-TKIs in the first-line treatment of EGFR mutation-positive advanced NSCLC, with a similar safety profile and lower rates of serious adverse events. (Funded by AstraZeneca; FLAURA ClinicalTrials.gov number, NCT02296125 .).info:eu-repo/semantics/publishedVersio

Charge and Spin Currents Generated by Dynamical Spins

We demonstrate theoretically that a charge current and a spin current are generated by spin dynamics in the presence of spin-orbit interaction in the perturbative regime. We consider a general spin-orbit interaction including the spatially inhomogeneous case. Spin current due to spin damping is identified as one origin of generated charge current, but other contributions exist, such as the one due to an induced conservative field and the one arising from the inhomogeneity of spin-orbit interaction.Comment: 14 pages, 4 figure

Spin Seebeck insulator

Thermoelectric generation is an essential function of future energy-saving technologies. However, this generation has been an exclusive feature of electric conductors, a situation which inflicts a heavy toll on its application; a conduction electron often becomes a nuisance in thermal design of devices. Here we report electric-voltage generation from heat flowing in an insulator. We reveal that, despite the absence of conduction electrons, a magnetic insulator LaY2Fe5O12 converts a heat flow into spin voltage. Attached Pt films transform this spin voltage into electric voltage by the inverse spin Hall effect. The experimental results require us to introduce thermally activated interface spin exchange between LaY2Fe5O12 and Pt. Our findings extend the range of potential materials for thermoelectric applications and provide a crucial piece of information for understanding the physics of the spin Seebeck effect.Comment: 19 pages, 5 figures (including supplementary information